TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05892107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toy Group
Description: After meeting the children in the toy group, the toy will be given to the children to play 1 minute before the procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mask group with cartoon characters
Description: The nurse who will open the vascular access with the children in the cartoon character mask group will meet the child 1 minute before the procedure with a cartoon character mask on his/her face.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: In the control group, the nurse who will open the vascular access will meet the child 1 minute before the procedure with a white mask on her/his face. Children in the control group will be subjected to routine procedures before blood collection.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
Study: NCT05593939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
Study: NCT04984330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
Study: NCT04929574

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram and Hematological Analysis
Description: Echocardiogram and Hematological Analysis
Study: NCT05561569

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: 23 gauge pars plana vitrectomy for managing primary retinal detachment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: 23 gauge pars plana vitrectomy for managing primary retinal detachment.
Study: NCT06360029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LvL UP
Description: The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LvL UP + MI
Description: After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
Study: NCT06358001

Intervention type: DEVICE
Intervention: EchoTip AcuCore
Description: Using endoscopic ultrasound guided needle to collect biopsies
Study: NCT05546242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir/Rilpivirine
Description: injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral
Description: Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
Study: NCT06495190

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry
Description: 52 g/d blueberry powder supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry
Description: 52 g/d blueberry powder supplement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Five 45-min walking sessions per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Five 45-min walking sessions per week
Study: NCT04667481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Intervention
Description: Participate in aerobic exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Intervention
Description: Participate in aerobic exercise intervention
Study: NCT06495190

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 52 g/d placebo powder supplement
Study: NCT04667481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Intervention
Description: Participate in resistance exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Intervention
Description: Participate in resistance exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention: Digital copies and outline of sessions
Description: Receive digital copy of AE and RE sessions and an outline of sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06495190

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 52 g/d placebo powder supplement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Five 45-min stretching sessions per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Five 45-min stretching sessions per week
Study: NCT06135376

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive multi-component interventions
Description: It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive multi-component interventions
Description: It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.
Study: NCT06166589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
Study: NCT06267872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF (labeled as AP 60-702)
Description: An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF (labeled as AP 60-702)
Description: An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.
Study: NCT06166589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.
Study: NCT06267872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Suspension (Alum)
Description: Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Suspension (Alum)
Description: Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.
Study: NCT06225999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection (S095013)
Description: Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LLV (levoisomer form of leucovorin)
Description: LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5- FU (5-Fluorouracil)
Description: 5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Study: NCT06553807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes.
Description: The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes. Pre-test and post-test will be applied to the participants after 4 weeks. Follow-up test data will be collected from the intervention and control groups after 3 months.
Study: NCT06555471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg iv q3w d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Extraperitoneal radiation therapy
Description: once a day, five times a week, at a dose of 1.8-2 Gy/f, for a total of 45-50.4 Gy. Radiation therapy starts from the first cycle of Sintilimab Injection combined with chemotherapy
Study: NCT06140680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifelongU
Description: The LifelongU intervention is an abbreviation name from LifelongU: Cultivating Physical Literacy for University \& Beyond. LifelongU is a unique and coined term that symbolizes the program's commitment to promoting physical literacy as a lifelong journey. It combines the words Lifelong and University to represent an intervention that focuses on physical literacy development not only during the university years but also throughout a person's entire life. The name is designed to convey the idea that physical literacy is an asset that will benefit individuals in all aspects of life, even after they leave the university.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical education
Description: The control group received 12-week traditional physical education lesson as usual.
Study: NCT05674370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRIP Electronic Diagnostic Chip
Description: Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory-based nucleic acid amplification tests (NAATs)
Description: Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab
Study: NCT05463354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: 1dose, Intramuscular Injection
Study: NCT06267872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Suspension (Alum)
Description: Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACU-026-001-1 (labeled as empty LNP)
Description: An AF consisting of 4 lipid components.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACU-026-001-1 (labeled as empty LNP)
Description: An AF consisting of 4 lipid components.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACU-026-001-1 (labeled as empty LNP)
Description: An AF consisting of 4 lipid components.
Study: NCT05695391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa (Recombinant)
Description: LR769
Study: NCT05923970

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology for antibody levels - Baseline
Description: Measurement of rubella IgG antibody levels at baseline

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology for antibody levels - Baseline
Description: Measurement of rubella IgG antibody levels at baseline

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology to assess cell mediated immune (CMI) response - Baseline
Description: Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology to assess cell mediated immune (CMI) response - Baseline
Description: Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.
Study: NCT05291910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study: NCT05923970

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology for antibody levels - Post third dose of MMR vaccine
Description: Measurement of rubella IgG antibody levels post third dose of MMR vaccine

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology to assess CMI - Post third dose of MMR vaccine
Description: Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.
Study: NCT05353036

Intervention type: OTHER
Intervention: Survey
Description: Survey assessing incidence, frequency, and type of illicit substance use
Study: NCT06563245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin for Injection
Description: 1.8mg/kg/dose (MAX 180 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin for Injection
Description: 1.8mg/kg/dose (MAX 180 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin for Injection
Description: 1.8mg/kg/dose (MAX 180 mg)
Study: NCT05291910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 130mg/m2, IV , D1, D8, q3w
Study: NCT06163157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue massage(CTM)
Description: CTM will be applied by a trained physiotherapist for 3 days/week for 4 weeks. Application time will be approximately 15-20 minutes.
Study: NCT06431880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External oblique intercostal plane block
Description: Patients will receive external oblique intercostal plane block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: Patients will receive thoracic paravertebral block
Study: NCT06001255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study: NCT04667949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Description: Subjects will receive fingolimod 0.5mg capsule QD up to month 24
Study: NCT04619602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSNO
Description: Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
Study: NCT06641011

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate restoration (resin- based) after blot-drying silver fluoride application
Description: Blot-drying silver fluoride with cotton pellet followed by resin-based fissure sealant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate restoration (GI- based) after blot-drying silver fluoride application
Description: Blot-drying silver fluoride with cotton pellet followed by glass ionomer-based fissure sealant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate restoration (Resin based) after rinsing silver fluoride application
Description: Rinsing silver fluoride off followed by resin-based fissure sealant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate restoration (GIC) after rinsing silver fluoride application
Description: Rinsing silver fluoride off and blot-drying of fissures followed by glass ionomer-based fissure sealant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin based fissure sealant restoration one week after silver fluoride (AgF) application
Description: Resin based fissure sealant restoration one week after silver fluoride (AgF) application

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GI- based fissure sealant restoration one week after silver fluoride (AgF) application
Description: GI- based fissure sealant restoration one week after silver fluoride (AgF) application